Download full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that its wholly-owned
Download full announcement Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has confidentially
NEW YORK, May 18, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), a commercial-stage artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that it has
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that at the general meeting of the Company held today the resolution to cancel the share premium account of the Company and
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that, following legal advice, it has taken the decision to remove the offering restrictions imposed by US securities law
Download full announcement Proposed capital reduction and notice of General Meeting Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that a circular (a “Circular”) will today be sent to
NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory
NEW YORK, April 27, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announced today that it has received ISO 13485:2016 certification for its development and commercial laboratory
Download full announcement Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX ™ platform will be used by investigators from the Icahn School of Medicine at Mount Sinai to
NEW YORK, April 20, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), the AIM-traded developer of clinical grade artificial intelligence in vitro diagnostics for kidney disease, announces that the KidneyIntelX™ platform will be used by investigators from the Icahn School of Medicine
